Agios Pharma (AGIO) Tops Q3 EPS by 6c

Agios Pharma (NASDAQ: AGIO) reported Q3 EPS of ($1.64), $0.06 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $7.34 million versus the consensus estimate of $7.64 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Morgan Stanley Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to Equalweight
• UBS Upgrades Solstice Advanced Materials Inc. (SOLS) to Buy